Eikon Therapeutics Prices 21.18M Shares at $18.00
Eikon Therapeutics priced 21.18M shares at $18.00. The deal size was increased from 17.65M and priced at the top end of the $16.00-$18.00 range. JPMorgan and Morgan Stanley are acting as joint book running managers for the offering. Eikon is a late-stage clinical biopharmaceutical company whose initial focus is oncology, where it says it is advancing a pipeline of drug candidates "targeting areas of high unmet need in large indications" for various cancers.
Trade with 70% Backtested Accuracy
Analyst Views on EIKN
No data
About EIKN
About the author
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
Amazon Takes Bold Steps in AI Investment, Posing Significant Risks for Markets.
Amazon's Spending Forecast: Amazon's recent spending forecast has surprised the markets, contrasting sharply with the prevailing risk-averse sentiment among investors.
Concerns Over AI Investments: This situation raises concerns about whether the current enthusiasm for artificial intelligence investments may mirror the speculative excesses seen during the dot-com bubble.
Liftoff Mobile Delays IPO Plans for the Time Being
- IPO Postponement: Liftoff Mobile has delayed its initial public offering (IPO) due to unfavorable market conditions.
- Market Impact: The decision follows a day marked by significant declines in stock prices.
Eikon Therapeutics Raises $381 Million in Upsized IPO
- Expanded Financing: Eikon Therapeutics successfully raised $381 million in its IPO by offering 21.2 million shares at $18 each, exceeding its original plan of 17.6 million shares, indicating strong market demand for its immuno-responsive cancer therapies.
- Listing Plans: The company intends to list on Nasdaq under the ticker EIKN, and this successful IPO will provide substantial funding for its ongoing research and development, facilitating further growth in the biotechnology sector.
- Strong Underwriting Team: J.P. Morgan, Morgan Stanley, BofA Securities, Cantor Fitzgerald, and Mizuho Securities acted as joint bookrunners for the deal, showcasing their influence and expertise in the capital markets.
- Positive Market Reaction: The success of this IPO not only reflects investor confidence in Eikon Therapeutics' future growth potential but also sends a positive signal to other biotech companies, potentially stimulating more IPO activities in the sector.
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
Amazon Takes Bold Steps in AI Investment, Posing Significant Risks for Markets.
Amazon's Spending Forecast: Amazon's recent spending forecast has surprised the markets, contrasting sharply with the prevailing risk-averse sentiment among investors.
Concerns Over AI Investments: This situation raises concerns about whether the current enthusiasm for artificial intelligence investments may mirror the speculative excesses seen during the dot-com bubble.
Liftoff Mobile Delays IPO Plans for the Time Being
- IPO Postponement: Liftoff Mobile has delayed its initial public offering (IPO) due to unfavorable market conditions.
- Market Impact: The decision follows a day marked by significant declines in stock prices.
Eikon Therapeutics Raises $381 Million in Upsized IPO
- Expanded Financing: Eikon Therapeutics successfully raised $381 million in its IPO by offering 21.2 million shares at $18 each, exceeding its original plan of 17.6 million shares, indicating strong market demand for its immuno-responsive cancer therapies.
- Listing Plans: The company intends to list on Nasdaq under the ticker EIKN, and this successful IPO will provide substantial funding for its ongoing research and development, facilitating further growth in the biotechnology sector.
- Strong Underwriting Team: J.P. Morgan, Morgan Stanley, BofA Securities, Cantor Fitzgerald, and Mizuho Securities acted as joint bookrunners for the deal, showcasing their influence and expertise in the capital markets.
- Positive Market Reaction: The success of this IPO not only reflects investor confidence in Eikon Therapeutics' future growth potential but also sends a positive signal to other biotech companies, potentially stimulating more IPO activities in the sector.
